In resected or irradiated stage II–IIIA RET fusion-positive NSCLC (n=109), adjuvant selpercatinib gave 2-year event-free survival of 92% vs 61% with placebo (HR 0.17). Grade ≥3 ALT/AST rises occurred in 17%/19% on selpercatinib.
RCTn = 151
Wu et al. Selpercatinib in Early-Stage RET Fusion-Positive Non-Small-Cell Lung Cancer